Funding will propel Leyden Labs’ non-vaccine intranasal antibody programs to safeguard people from respiratory viruses. The programs are based on Leyden Labs’ Mucosal Protection Platform utilizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback